1
|
Ivleva VB, Gowetski DB, Lei QP. Streamlining Peptide Mapping LC-MS Approach for Studying Fusion Peptide-Conjugated Vaccine Immunogens. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:2777-2790. [PMID: 34751576 PMCID: PMC10157672 DOI: 10.1021/jasms.1c00211] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
A newly introduced HIV-1 vaccination utilizes a fusion peptide (FP)-based immunogen-carrier conjugate system, where the FP is coupled to a protein carrier via a bifunctional linker. Such heterogeneous materials present a challenge for the routine product quality assessment. Peptide mapping LC-MS analysis has become an indispensable tool for assessing the site-specific conjugation ratio, estimating site occupancy, monitoring conjugation profiles, and analyzing post-translational modifications (PTMs) and disulfide bonds as well as high-order protein structures. To streamline the peptide mapping approach to match the needs of a fast-paced conjugate vaccine product characterization, a selection of signature fragment ions generated by MSE fragmentation was successfully applied to assess the product quality at the different stages of a conjugates' manufacturing process with an emphasis on monitoring the amount of a reactive linker. This technique was employed in different conjugation studies of the protein carriers, linkers, and FP compositions as well as the cross-linked species formed during stress-degradation studies. Multiple derivatives of the intermediate and final conjugated products formed during a multistaged synthesis were monitored by means of the sensitive extracted-ion chromatogram (XIC) profiling and were included in the estimation of the site-specific conjugation loads. Differentiation of the conjugates with various FP compositions was demonstrated. The conjugation site occupancy was evaluated with respect to the solvent exposure of Lys residues. The findings of these LC-MS studies greatly aided in choosing the best conjugation strategy to ensure that the final recombinant tetanus toxoid heavy chain (rTTHc) product is chemically inert and represents a safe vaccine candidate for clinical evaluation.
Collapse
Affiliation(s)
- Vera B Ivleva
- Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Gaithersburg, Maryland 20878, United States
| | - Daniel B Gowetski
- Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Gaithersburg, Maryland 20878, United States
| | - Q Paula Lei
- Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Gaithersburg, Maryland 20878, United States
| |
Collapse
|
2
|
Yan L, Nan X, Zhang C, Wang H, Huang X, Hu J, Liu Y. Development of an enzyme‑linked immunosorbent assay for camptothecin. Mol Med Rep 2019; 20:959-966. [PMID: 31173229 PMCID: PMC6625201 DOI: 10.3892/mmr.2019.10342] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 05/10/2019] [Indexed: 11/06/2022] Open
Abstract
The use of camptothecin and its analogues has increased in clinical settings and in agriculture. Therefore, camptothecins and their derivatives, metabolites and degradation products are frequently found in the environment. Therefore, it is important to develop an ELISA for the quantification of camptothecins in human plasma, plants, animal tissues and other matrices. The present study developed a novel competitive indirect ELISA for camptothecin using a monoclonal antibody (MAb). In total, two haptens and various carrier proteins were tested to select the most suitable immunogen for the production of MAbs against camptothecin. Hapten 1 conjugated with keyhole limpet hemocyanin was selected for the preparation of MAb 5A3, and was used to establish a competitive indirect ELISA for camptothecin. A total of three derivatives of camptothecin used in clinical practice were examined. Topotecan showed an IC50 value of 0.68 µg/ml with a detection limit of 0.19 µg/ml, belotecan showed an IC50 value of 0.87 µg/ml with a detection limit of 0.22 µg/ml and irinotecan showed an IC50 value of 2.85 µg/ml with a detection limit of 0.47 µg/ml. The cross-reactivity results suggested that the assay developed in the present study possessed a high sensitivity to camptothecin. Therefore, this immunoassay technique may be suitable for monitoring the levels of camptothecin in compound analysis, clinical applications, and analyses of food and environmental samples.
Collapse
Affiliation(s)
- Liting Yan
- Central Laboratory, Shaanxi Provincial People's Hospital, Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi 710068, P.R. China
| | - Xiang Nan
- School of Pharmacy, Lanzhou University, Lanzhou, Gansu 730000, P.R. China
| | - Cunzheng Zhang
- Institute of Food Quality and Safety Inspection, Jiangsu Academy of Agricultural Sciences, Nanjing, Jiangsu 210014, P.R. China
| | - Haifang Wang
- Institute of Integrated Medicine, Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi 712046, P.R. China
| | - Xiaoyan Huang
- Central Laboratory, Shaanxi Provincial People's Hospital, Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi 710068, P.R. China
| | - Jun Hu
- Central Laboratory, Shaanxi Provincial People's Hospital, Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi 710068, P.R. China
| | - Yingqian Liu
- School of Pharmacy, Lanzhou University, Lanzhou, Gansu 730000, P.R. China
| |
Collapse
|
3
|
Walczak M, Grzywa R, Łupicka-Słowik A, Skoreński M, Bobrek K, Nowak D, Boivin S, Brown EL, Oleksyszyn J, Sieńczyk M. Method for generation of peptide-specific IgY antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope. Biopolymers 2016; 104:552-9. [PMID: 26095000 DOI: 10.1002/bip.22695] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Revised: 05/07/2015] [Accepted: 06/09/2015] [Indexed: 12/21/2022]
Abstract
The IgY antibodies offer an attractive alternative to mammalian IgGs in research, diagnosis and medicine. The isolation of immunoglobulin Y from the egg yolks is efficient and economical, causing minimal suffering to animals. Here we present the methodology for the production of IgY antibodies specific to Staphylococcus aureus fibrinogen binding protein (Efb) and its peptidyl epitope (spanning residues 127-140). The Efb is an extracellular, adhesion protein which binds both human fibrinogen and complement C3 protein thus contributing to the high infectious potential of this pathogen. The selected epitope of Efb protein is responsible for the interaction with C3. The immunochemical characterization of both anti-Efb and epitope-specific IgY antibodies revealed their similar avidity, titer, and reactivity profile, although some differences in the hen's immune response to administered antigens is discussed.
Collapse
Affiliation(s)
- Maciej Walczak
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| | - Renata Grzywa
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| | - Agnieszka Łupicka-Słowik
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| | - Marcin Skoreński
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| | - Kamila Bobrek
- Department of Epizootiology and Clinic of Bird and Exotic Animals, Wroclaw University of Environmental and Life Sciences, Faculty of Veterinary Medicine, Pl. Grunwaldzki 45, 50-366, Wroclaw, Poland
| | - Daria Nowak
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| | - Stephane Boivin
- European Molecular Biology Laboratory (EMBL), Hamburg Outstation, Notkestrasse 85, 22607, Hamburg, Germany
| | - Eric L Brown
- Center for Infectious Disease, Division of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Science Center, Houston, TX, USA
| | - Józef Oleksyszyn
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| | - Marcin Sieńczyk
- Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Faculty of Chemistry, Wybrzeze Wyspianskiego 27, 50-370, Wroclaw, Poland
| |
Collapse
|
4
|
Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG. Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells. Nanomedicine (Lond) 2013; 7:1591-610. [PMID: 23148541 DOI: 10.2217/nnm.12.131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Current retroviral treatments have reduced AIDS to a chronic disease for most patients. However, given drug-related side effects, the emergence of drug-resistant strains and the persistence of viral replication, the development of alternative treatments is a pressing need. This review focuses on recent developments in HIV immunotherapy treatments, with particular emphasis on current vaccination strategies for optimizing the induction of an effective immune response by the recruitment of dendritic cells. In addition to cell-based therapies, targeted strategies aiming to deliver synthetic HIV peptides to dendritic cell-specific receptors in vivo will be discussed.
Collapse
Affiliation(s)
- Luis J Cruz
- Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
| | | | | | | | | | | |
Collapse
|
5
|
Lu X, Chen D, Endresz V, Xia M, Faludi I, Burian K, Szabo A, Csanadi A, Miczak A, Gonczol E, Kakkar V. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice. Atherosclerosis 2010; 212:472-80. [PMID: 20609438 DOI: 10.1016/j.atherosclerosis.2010.06.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2010] [Revised: 06/02/2010] [Accepted: 06/03/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVE HSP60 is emerging as an immunodominant target of autoantibodies in atherosclerosis and recent studies have revealed oxLDL as a key antigen in the development of atherosclerosis. In this study, we assay whether immunizing Apobtm2SgyLdlrtm1Her/J mice with a combination of ApoB and human HSP60 peptides has an additive effect on atheroprotection compared to ApoB or HSP60 peptides applied alone by following atherosclerotic lesion development. METHODS AND RESULTS In this study, 2 weeks after the first immunization, Apobtm2SgyLdlrtm1Her/J mice were placed on a high-fat diet for 8 weeks followed by 2 weeks on a normal diet allowing the mice to adapt to the environment before sacrifice. High levels of ApoB and HSP60 antibodies were detectable in week 2 and week 12 following the first immunization with KLH-conjugated ApoB and HSP60 peptides either individually or in combination. Histological analyses demonstrated that mice immunized with both, ApoB and HSP60 peptides, showed the most significant reduction in atherosclerotic lesions (41.3%; p<0.001) compared to a reduction of 14.7% (p<0.05) and 21.1% (p<0.01) in mice immunized with ApoB or HSP60 peptides, respectively; control mice were immunized with either PBS or adjuvant alone. These results were further supported by significant differences in the cellular and humoral immune responses between test animals. CONCLUSIONS Immunization with a combination of ApoB and HSP60 peptide antigens significantly reduced early atherosclerotic lesions in the Apobtm2SgyLdlrtm1Her/J mouse model of atherosclerosis. This approach offers promise as a novel strategy for developing anti-atherosclerotic agents.
Collapse
Affiliation(s)
- Xinjie Lu
- Thrombosis Research Institute, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.provac.2010.07.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|